Cargando…

Sanziguben polysaccharides inhibit diabetic nephropathy through NF-κB-mediated anti-inflammation

BACKGROUND: Sanziguben polysaccharides (SZP) are large amounts of classical Chinese medicines from Sanziguben (SZGB). Moreover, SZGB is a widely applied compound prescription for diabetic nephropathy (DN) treatment, but the role is still unclear. This study initially explores the mechanism of SZP in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Kang, Zhang, Jianing, Liu, Chang, Ou, Lijuan, Wang, Fan, Yu, Yang, Wang, Yumei, Bai, Shasha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425148/
https://www.ncbi.nlm.nih.gov/pubmed/34493288
http://dx.doi.org/10.1186/s12986-021-00601-z
_version_ 1783749800055799808
author Zhou, Kang
Zhang, Jianing
Liu, Chang
Ou, Lijuan
Wang, Fan
Yu, Yang
Wang, Yumei
Bai, Shasha
author_facet Zhou, Kang
Zhang, Jianing
Liu, Chang
Ou, Lijuan
Wang, Fan
Yu, Yang
Wang, Yumei
Bai, Shasha
author_sort Zhou, Kang
collection PubMed
description BACKGROUND: Sanziguben polysaccharides (SZP) are large amounts of classical Chinese medicines from Sanziguben (SZGB). Moreover, SZGB is a widely applied compound prescription for diabetic nephropathy (DN) treatment, but the role is still unclear. This study initially explores the mechanism of SZP in the treatment of DN. METHODS: The high-fat diet plus streptozotocin injections were used to replicate the DN models in male C57BL/6 mice. DN mice were divided into five groups: DN mice, DN mice treated with SZP(1.01 or 2.02 g/kg), DN mice treated with SZGB decoction(4.7 g/kg), and DN mice treated with metformin (300 mg/kg). HG and LPS plus TNFα stimulated human tubule epithelial (HK-2) cells to establish an in vitro model and treated with SZP (100 or 200 μg/mL). RESULTS: SZP was found to comprise sugar, protein, and uronic acid. Furthermore, SZP alleviated the progression of inflammation in vivo and in vitro by inhibiting the expression of NF-κB. CONCLUSIONS: NF-κB plays a critical role in the development of DN induced by STZ and HG. Furthermore, SZP can attenuate the NF-κB‐mediated progression of diabetic nephropathy, improve DN through anti-inflammation.
format Online
Article
Text
id pubmed-8425148
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-84251482021-09-10 Sanziguben polysaccharides inhibit diabetic nephropathy through NF-κB-mediated anti-inflammation Zhou, Kang Zhang, Jianing Liu, Chang Ou, Lijuan Wang, Fan Yu, Yang Wang, Yumei Bai, Shasha Nutr Metab (Lond) Research BACKGROUND: Sanziguben polysaccharides (SZP) are large amounts of classical Chinese medicines from Sanziguben (SZGB). Moreover, SZGB is a widely applied compound prescription for diabetic nephropathy (DN) treatment, but the role is still unclear. This study initially explores the mechanism of SZP in the treatment of DN. METHODS: The high-fat diet plus streptozotocin injections were used to replicate the DN models in male C57BL/6 mice. DN mice were divided into five groups: DN mice, DN mice treated with SZP(1.01 or 2.02 g/kg), DN mice treated with SZGB decoction(4.7 g/kg), and DN mice treated with metformin (300 mg/kg). HG and LPS plus TNFα stimulated human tubule epithelial (HK-2) cells to establish an in vitro model and treated with SZP (100 or 200 μg/mL). RESULTS: SZP was found to comprise sugar, protein, and uronic acid. Furthermore, SZP alleviated the progression of inflammation in vivo and in vitro by inhibiting the expression of NF-κB. CONCLUSIONS: NF-κB plays a critical role in the development of DN induced by STZ and HG. Furthermore, SZP can attenuate the NF-κB‐mediated progression of diabetic nephropathy, improve DN through anti-inflammation. BioMed Central 2021-09-07 /pmc/articles/PMC8425148/ /pubmed/34493288 http://dx.doi.org/10.1186/s12986-021-00601-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zhou, Kang
Zhang, Jianing
Liu, Chang
Ou, Lijuan
Wang, Fan
Yu, Yang
Wang, Yumei
Bai, Shasha
Sanziguben polysaccharides inhibit diabetic nephropathy through NF-κB-mediated anti-inflammation
title Sanziguben polysaccharides inhibit diabetic nephropathy through NF-κB-mediated anti-inflammation
title_full Sanziguben polysaccharides inhibit diabetic nephropathy through NF-κB-mediated anti-inflammation
title_fullStr Sanziguben polysaccharides inhibit diabetic nephropathy through NF-κB-mediated anti-inflammation
title_full_unstemmed Sanziguben polysaccharides inhibit diabetic nephropathy through NF-κB-mediated anti-inflammation
title_short Sanziguben polysaccharides inhibit diabetic nephropathy through NF-κB-mediated anti-inflammation
title_sort sanziguben polysaccharides inhibit diabetic nephropathy through nf-κb-mediated anti-inflammation
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425148/
https://www.ncbi.nlm.nih.gov/pubmed/34493288
http://dx.doi.org/10.1186/s12986-021-00601-z
work_keys_str_mv AT zhoukang sanzigubenpolysaccharidesinhibitdiabeticnephropathythroughnfkbmediatedantiinflammation
AT zhangjianing sanzigubenpolysaccharidesinhibitdiabeticnephropathythroughnfkbmediatedantiinflammation
AT liuchang sanzigubenpolysaccharidesinhibitdiabeticnephropathythroughnfkbmediatedantiinflammation
AT oulijuan sanzigubenpolysaccharidesinhibitdiabeticnephropathythroughnfkbmediatedantiinflammation
AT wangfan sanzigubenpolysaccharidesinhibitdiabeticnephropathythroughnfkbmediatedantiinflammation
AT yuyang sanzigubenpolysaccharidesinhibitdiabeticnephropathythroughnfkbmediatedantiinflammation
AT wangyumei sanzigubenpolysaccharidesinhibitdiabeticnephropathythroughnfkbmediatedantiinflammation
AT baishasha sanzigubenpolysaccharidesinhibitdiabeticnephropathythroughnfkbmediatedantiinflammation